Document is current

Article History

Received: 8 February 2024

Accepted: 8 November 2024

First Online: 20 November 2024

Declarations

:

: All participants provided informed consent prior to completing the survey and could withdraw at any time, and participants who completed the entire survey received a modest monetary incentive. The study protocol was submitted to the WCG Institutional Review Board for ethical approval and was determined to qualify for exemption status because sufficient protections were in place to protect the privacy of subjects and to maintain the confidentiality of data. The study and data accumulation were in conformity with all country, federal, or state laws, and the study adhered to the tenets of the Declaration of Helsinki.

: Not applicable.

: O.A.S. is on the Speakers’ Bureau for United Therapeutics Corporation and is a consultant for Altavant Sciences Inc, Acceleron Pharma Inc, and Merck; she is also on an advisory board for Janssen Pharmaceuticals and received support from Ferrer for travel to meetings. A.V. is a consultant for United Therapeutics Corporation, Merck, and Janssen Pharmaceuticals; she is also on the Speakers’ Bureau for United Therapeutics Corporation, Janssen Pharmaceuticals, and Bayer. M.R.S. and M.B. are employees and shareholders of United Therapeutics Corporation.